Analysis of the PDL1 landscape using Single Cell Approaches for Profiling Patient Response


  • Dr Moshe Feldman, Director of Translational Cancer Immunology, Center for Cancer Research, Massachusetts General Hospital, The Broad Institute
  • Dr Deena Soni, Global Marketing Manager, Sony Biotechnology Inc
  • Dr Nicole Abreu, Science and Technology Advisor, 10x Genomics

Immune-based therapies targeting the inhibitory receptors (PD-L1, PD1, and CTLA4) are proven to be effective to treat malignancies ranging from non-small cell lung cancer to Merkel cell carcinoma. But some patients do not respond or stop responding within the first year of therapy. Identifying the underlying mechanisms associated with these variable response rates remains an important open research challenge in clinical oncology.

Join our commercial tutorial to learn how a team of researchers at Massachusetts General Hospital are using combinatorial approaches to analyze single cells from patients to explore the mechanisms of PD-L1 resistance in cancer and treatment response. Technologies from Sony and 10x Genomics used for single cell isolation and analysis of immune cells in this study will also be discussed.

JEM's 125th Anniversary: Over a Century of Novel Conceptual Insights


  • Akiko Iwasaki, Ph.D.
  • Joseph Sun, Ph.D.
  • Gwen Randolph, Ph.D.
  • Stephanie Eisenbarth, MD, Ph.D
  • Ali Ellebedy, Ph.D.

Since its inception in 1896, Journal of Experimental Medicine (JEM) has been a leader in publishing outstanding and enduring studies in medical biology, and has greatly contributed to the fields of immunology, cancer biology, vascular biology, microbial pathogenesis, neuroscience, and stem cell biology. Join us for our Wednesday Workshop for presentations by guest speakers on exciting research featured in JEM and to learn about publishing from scientific editors.

Diagnosis, Treatment, and Immunopathogenesis of Chronic COVID-19 (PASC)


  • Bruce K. Patterson, MD, CEO & Founder of InCellDX
  • Miguel Tam, Ph.D., Director, Strategic Marketing

Some people with COVID-19 experience lingering symptoms for weeks or months, known as post-acute sequelae SARS-CoV-2 infection (PASC). Dr. Bruce Patterson, CEO & Founder of InCellDX, will share the story of 3,000 “long haulers” in his group’s Chronic COVID Treatment Center™ program, a collaboration between research facilities, clinicians, and medical laboratories. He will discuss novel tools developed with BioLegend to diagnose, treat, and discover the possible underlying immunologic mechanisms in PASC and the debilitating effects on those suffering from these sequelae even a year later.

Key Considerations when Selecting an Immunoassay for Your Research 

Millipore Sigma logo


  • Lawrence Rentoul, Segment Lead, ELISAs and Specialty Assays
  • Alex Ko, Global Product Manager, SMC™
  • Brooke Gilliam, Global Product Manager, MILLIPLEX®

Researchers rely on immunoassays to study biomarker expression in a variety of sample types. We are committed to delivering the best possible immunoassays for your research needs. Whether you need ultrasensitive detection offered by Single Molecule Counting (SMC™) technology, highly verified Conferma™ ELISAs, or industry-leading MILLIPLEX® multiplex kits using Luminex® xMAP® technology, you can expect reliable measurements, intuitive user experience, and knowledgeable scientific partners to drive your biomarker project from hypothesis to publication. This workshop will detail the history of our immunoassay platforms and advantages of using each one in biomarker research.

New Dye Technology: Unlock the Full Potential of Your Flow Cytometry Experiment


  • Seddon Thomas, Ph.D., Staff Scientist

Fluorescent dye performance heavily impacts both the quality and the dimensionality of flow cytometry experiments. For example, PE-based tandems, although bright, are notoriously cross-excited by multiple laser lines and introduce substantial fluorescence into off-target channels, compromising the full potential of blue and yellow-green lasers. New Invitrogen™ NovaFluor™ dyes use the Invitrogen™ Phiton™ DNA Platform to engineer excitation and emission spectra. The spectral cleanliness of the Nova Fluor technology simplifies and expands future panel design. 

Introducing RoboSep™-C: Closed, Automated Cell Separation for Faster and Easier Large-Scale Human Immune Cell Isolation 

Stemcell Technologies logo


  • Vesna Posarac, MSc, Senior Scientist 

Current methods for large-scale cell isolation can be a major operational bottleneck for many labs. Large-scale cell isolation often requires a full day to process a single leukapheresis sample and multiple instruments for higher sample throughput. This workshop will introduce RoboSep™-C, a new instrument for efficient, automated cell isolation in a closed system that takes less than 90 minutes. By automating sample processing, and easily integrating upstream of existing cell expansion, genome editing, and cryopreservation protocols, RoboSep™-C enables researchers to simultaneously scale up and streamline their operations.